GSK
891 hedge funds and large institutions have $12.7B invested in GSK in 2024 Q3 according to their latest regulatory filings, with 90 funds opening new positions, 304 increasing their positions, 318 reducing their positions, and 67 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
891
Holders Change
+16
Holders Change %
+1.83%
% of All Funds
12.89%
Holding in Top 10
10
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.14%
New
90
Increased
304
Reduced
318
Closed
67
Calls
$200M
Puts
$104M
Net Calls
+$96.4M
Net Calls Change
+$32.9M
Top Buyers
| 1 |
Goldman Sachs
New York
|
$301M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
$166M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
$1.19B |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
$212M |
| 5 |
Millennium Management
New York
|
$59.6M |
Top Sellers
| 1 |
Holocene Advisors
New York
|
$2.67M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
$308M |
| 3 |
Morgan Stanley
New York
|
$325M |
| 4 |
LP
LMR Partners
London,
United Kingdom
|
$82.5M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
$30.7M |
